Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population

Angiology

Volumn 65, Issue 7, 2014, Pages 634-640

  Li, Yan ^a   Lu, Jiapeng ^a   Wu, Xiaogang ^a   Yang, Chunlei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

atherosclerosis; peripheral artery disease; serum uric acid

Indexed keywords

URIC ACID; BIOLOGICAL MARKER;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; ASYMPTOMATIC DISEASE; B SCAN; CARDIOANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORGAN INJURY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION; URIC ACID BLOOD LEVEL; URINALYSIS; VERY ELDERLY; ALBUMINURIA; BLOOD; COMPLICATION; HYPERTENSION; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; HUMANS; HYPERTENSION; HYPERURICEMIA; MALE; MIDDLE AGED; RISK FACTORS; URIC ACID; VASCULAR STIFFNESS;

EID: 84903822626     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713513143     Document Type: Article

References (57)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2007 ; 28 (12). 1462-1536
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21(6): 1011-1153.
3. Viazzi F, Leoncini G, Parodi D, et al. Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. J Am Soc Nephrol. 2005 ; 16 (suppl 1). S89 - S91
4. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993 ; 87 (3 suppl). II56 - II65
5. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011 ; 18 (11). 924-938
6. Reed JF III, Eid S, Edris B, Sumner AD. Prevalence of peripheral artery disease varies significantly depending upon the method of calculating ankle brachial index. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (3). 377-381
7. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000 ; 35 (4). 898-903
8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 ; 351 (13). 1296-1305
9. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey. JAMA. 2000 ; 283 (18). 2404-2410
10. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization monitoring trends and determinants in cardiovascular diseases. Epidemiology. 1999 ; 10 (4). 391-397
11. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004 ; 164 (14). 1546-1551
12. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med. 1999 ; 131 (1). 7-13
13. Sakata K, Hashimoto T, Ueshima H, Okayama A. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. national integrated projects for prospective observation of non-communicable diseases and its trend in the aged. Eur J Epidemiol. 2001 ; 17 (5). 461-468
14. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide. 2013 ; 32: 36-42
15. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008 ; 26 (2). 269-275
16. Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed). 2012 ; 17: 656-669
17. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005 ; 25 (1). 39-42
18. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991 ; 266 (13). 8604-8608
19. Liu J, Hong Y, D'Agostino RB, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA. 2004 ; 291 (21). 2591-2599
20. Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European lacidipine study on atherosclerosis (ELSA). J Hypertens. 2001 ; 19 (11). 1981-1989
21. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). an update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012 ; 34 (4). 290-296
22. Kim ES, Kwon HS, Ahn CW, et al. Serum uric acid level is associated with metabolic syndrome and microalbuminuria in Korean patients with type 2 diabetes mellitus. J Diabetes Complications. 2011 ; 25 (5). 309-313
23. Fukui M, Tanaka M, Shiraishi E, et al. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism. 2008 ; 57 (5). 625-629
24. Viazzi F, Leoncini G, Ratto E, et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens. 2007 ; 20 (12). 1276-1282
25. Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005 ; 45 (5). 991-996
26. Chang HY, Lee PH, Lei CC, et al. Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in Taiwan. PLoS One. 2013 ; 8 (4). e61450
27. Yu TF, Berger L. Impaired renal function gout: its association with hypertensive vascular disease and intrinsic renal disease. Am J Med. 1982 ; 72 (1). 95-100
28. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002 ; 47 (6). 610-613
29. Feringa HH, Bax JJ, van Waning VH, et al. The long-term prognostic value of the resting and postexercise ankle-brachial index. Arch Intern Med. 2006 ; 166 (5). 529-535
30. Langlois M, De Bacquer D, Duprez D, De Buyzere M, Delanghe J, Blaton V. Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis. 2003 ; 168 (1). 163-168
31. Shankar A, Klein BE, Nieto FJ, Klein R. Association between serum uric acid level and peripheral arterial disease. Atherosclerosis. 2008 ; 196 (2). 749-755
32. Tseng CH. Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with type 2 diabetes. Diabet Med. 2004 ; 21 (7). 724-729
33. Tseng CH. Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese type 2 diabetic patients. Circ J. 2007 ; 71 (7). 1131-1136
34. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol. 1988 ; 41 (3). 237-242
35. Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh). 1977 ; 85 (1). 198-208
36. Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005 ; 25 (5). 425-433
37. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005 ; 67 (5). 1739-1742
38. Jaramillo M, Naccache PH, Olivier M. Monosodium urate crystals synergize with IFN-gamma to generate macrophage nitric oxide: involvement of extracellular signal-regulated kinase 1/2 and NF-kappa B. J Immunol. 2004 ; 172 (9). 5734-5742
39. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005 ; 69 (8). 928-933
40. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006 ; 27 (10). 1174-1181
41. Tsioufis C, Kyvelou S, Dimitriadis K, et al. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Hum Hypertens. 2011 ; 25 (9). 554-559
42. Tomiyama H, Yamashina A, Arai T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement - a survey of 12517 subjects. Atherosclerosis. 2003 ; 166 (2). 303-309
43. Tsai WC, Huang YY, Lin CC, et al. Uric acid is an independent predictor of arterial stiffness in hypertensive patients. Heart Vessels. 2009 ; 24 (5). 371-375
44. Kim YJ, Cho BM, Lee S. Metabolic syndrome and arterial pulse wave velocity. Acta Cardiol. 2010 ; 65 (3). 315-321
45. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in communities. Ann Epidemiol. 1996 ; 6 (4). 331-340
46. Oikonen M, Wendelin-Saarenhovi M, Lyytikainen LP, et al. Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. Atherosclerosis. 2012 ; 223 (2). 497-503
47. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 ; 359 (17). 1811-1821
48. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood. 1997 ; 89 (2). 577-582
49. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension. 2003 ; 41 (6). 1183-1190
50. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis. 2000 ; 148 (1). 131-139
51. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr. 1991 ; 54 (6 suppl). 1129S - 1134
52. Tsioufis C, Chatzis D, Vezali E, et al. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens. 2005 ; 19 (3). 211-217
53. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005 ; 11 (32). 4161-4175
54. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study. Am J Kidney Dis. 2004 ; 43 (4). 589-599
55. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007 ; 22 (1). 118-127
56. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004 ; 55 (1). 53-62
57. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997 ; 20 (12). 1891-1895